SiSaf to seek FDA Orphan Drug Designation for SIS-101-ADO

SiSaf will seek regulatory approval for SIS-101-ADO to treat Autosomal Dominant Osteopetrosis Type 2. Credit: SiSaf.



  • SiSaf